Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 586,781
  • Shares Outstanding, K 71,125
  • Annual Sales, $ 430 K
  • Annual Income, $ -88,450 K
  • EBIT $ -100 M
  • EBITDA $ -102 M
  • 60-Month Beta 0.15
  • Price/Sales 1,365.73
  • Price/Cash Flow N/A
  • Price/Book 4.36

Options Overview Details

View History
  • Implied Volatility 99.14% ( +1.31%)
  • Historical Volatility 112.30%
  • IV Percentile 15%
  • IV Rank 19.91%
  • IV High 240.76% on 01/25/24
  • IV Low 63.93% on 09/25/24
  • Put/Call Vol Ratio 0.10
  • Today's Volume 12,818
  • Volume Avg (30-Day) 10,080
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 150,744
  • Open Int (30-Day) 143,828

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.34
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.39
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.70 +7.08%
on 12/18/24
10.88 -24.17%
on 12/04/24
+0.20 (+2.48%)
since 11/20/24
3-Month
5.86 +40.78%
on 10/01/24
11.16 -26.08%
on 11/13/24
+0.46 (+5.91%)
since 09/20/24
52-Week
5.28 +56.40%
on 08/05/24
14.84 -44.41%
on 02/28/24
+0.27 (+3.38%)
since 12/20/23

Most Recent Stories

More News
Why Altimmune Was Such a Robustly Healthy Stock on Thursday

Altimmune (NASDAQ: ALT) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized...

ALT : 8.25 (+0.86%)
Altimmune, Inc. Added to Nasdaq Biotechnology Index Effective December 23, 2024

Altimmune, Inc. will join the Nasdaq Biotechnology Index on December 23, 2024, highlighting its progress and upcoming clinical milestones.Quiver AI SummaryAltimmune, Inc., a clinical-stage biopharmaceutical...

ALT : 8.25 (+0.86%)
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds

The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.

IBB : 132.73 (+1.16%)
ALT : 8.25 (+0.86%)
Altimmune Added to Nasdaq Biotechnology Index

ALT : 8.25 (+0.86%)
Altimmune, Inc. Announces Presentation of Pemvidutide Body Composition Data at International Conference on Sarcopenia and Cachexia

Altimmune's CMO will present Phase 2 trial data on pemvidutide for obesity at an upcoming conference in Washington, D.C.Quiver AI SummaryAltimmune, Inc. has announced that its Chief Medical Officer, Dr....

ALT : 8.25 (+0.86%)
Altimmune Stock Up More Than 25% in a Month: Here's Why

Altimmune ALT is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction-associated steatohepatitis...

IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
ALT : 8.25 (+0.86%)
SPRO : 0.9551 (-4.30%)
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

ALT : 8.25 (+0.86%)
Altimmune to Participate at Two Upcoming Investor Conferences

ALT : 8.25 (+0.86%)
Altimmune, Inc. Reports Promising Phase 1b Trial Results for Pemvidutide in Reducing Cardio-Inflammatory and Hepato-Inflammatory Lipids in Patients with MASH

Pemvidutide showed significant reductions in inflammatory lipids, supporting its potential benefits for metabolic dysfunction-related conditions.Quiver AI SummaryAltimmune, Inc. announced favorable results...

ALT : 8.25 (+0.86%)
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

ALT : 8.25 (+0.86%)

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 9.18
2nd Resistance Point 8.96
1st Resistance Point 8.61
Last Price 8.25
1st Support Level 8.04
2nd Support Level 7.82
3rd Support Level 7.47

See More

52-Week High 14.84
Fibonacci 61.8% 11.19
Fibonacci 50% 10.06
Fibonacci 38.2% 8.93
Last Price 8.25
52-Week Low 5.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar